相似文献
1
NCCN CNS tumor guidelines update for 2023.2023年美国国立综合癌症网络（NCCN）中枢神经系统肿瘤指南更新
Neuro Oncol. 2023 Dec 8;25(12):2114-2116. doi: 10.1093/neuonc/noad169.
2
Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology.中枢神经系统癌症，第 3.2020 版，NCCN 肿瘤学临床实践指南。
J Natl Compr Canc Netw. 2020 Nov 2;18(11):1537-1570. doi: 10.6004/jnccn.2020.0052.
3
Central Nervous System Cancers, Version 1.2015.中枢神经系统癌症，第 1.2015 版。
J Natl Compr Canc Netw. 2015 Oct;13(10):1191-202. doi: 10.6004/jnccn.2015.0148.
4
NCCN Guidelines® Insights: Central Nervous System Cancers, Version 2.2022.NCCN 指南®洞察：中枢神经系统肿瘤，第 2.2022 版。
J Natl Compr Canc Netw. 2023 Jan;21(1):12-20. doi: 10.6004/jnccn.2023.0002.
5
Guidelines in the management of CNS tumors.中枢神经系统肿瘤的治疗指南。
J Neurooncol. 2021 Feb;151(3):345-359. doi: 10.1007/s11060-020-03530-8. Epub 2021 Feb 21.
6
NCCN Guidelines(R) Updates.美国国立综合癌症网络（NCCN）指南更新
J Natl Compr Canc Netw. 2013 Sep 1;11(9):xxxii-xxxvi.
7
Pediatric Central Nervous System Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology.儿童中枢神经系统肿瘤，2023 年第 2 版，NCCN 肿瘤学临床实践指南。
J Natl Compr Canc Netw. 2022 Dec;20(12):1339-1362. doi: 10.6004/jnccn.2022.0062.
8
An estimate of rate of deviation from NCCN guideline recommendations for central nervous system imaging in trials forming basis for drug approval in first line advanced non-small cell lung cancer (NSCLC).评估临床试验中中枢神经系统成像偏离 NCCN 指南建议的比率，这些临床试验构成了一线晚期非小细胞肺癌 (NSCLC) 药物批准的基础。
BMC Cancer. 2022 Jan 16;22(1):70. doi: 10.1186/s12885-022-09179-y.
9
Integrating Genomics Into Neuro-Oncology Clinical Trials and Practice.将基因组学整合到神经肿瘤学临床试验与实践中。
Am Soc Clin Oncol Educ Book. 2018 May 23;38:148-157. doi: 10.1200/EDBK_200989.
10
[The First Step in a Long-Run-Celebrating the announcement of "Guideline for the management of CNS gliomas in China"].[漫长征程的第一步——庆祝《中国中枢神经系统胶质瘤诊疗指南》发布]
Zhonghua Yi Xue Za Zhi. 2013 Aug 20;93(31):2417.
引用本文的文献
1
Dexamethasone in brain tumor patients: a real-world pharmacovigilance audit.脑肿瘤患者使用地塞米松：一项真实世界的药物警戒审计
Front Neurol. 2025 Aug 20;16:1632231. doi: 10.3389/fneur.2025.1632231. eCollection 2025.
2
Impact of Irradiation on Post-Surgical Residuals of WHO Grade I Meningioma.放疗对世界卫生组织一级脑膜瘤术后残留的影响。
J Clin Med. 2025 Aug 18;14(16):5829. doi: 10.3390/jcm14165829.
3
Clinical Predictors and Recurrence Characteristics Following Radiotherapy for Primary Central Nervous System Lymphoma: A Retrospective Cohort Study.原发性中枢神经系统淋巴瘤放疗后的临床预测因素及复发特征：一项回顾性队列研究
Cancers (Basel). 2025 Jun 27;17(13):2176. doi: 10.3390/cancers17132176.
4
Editorial: Clinical therapy of brain tumors.社论：脑肿瘤的临床治疗
Front Neurol. 2025 May 23;16:1610463. doi: 10.3389/fneur.2025.1610463. eCollection 2025.
5
Brain Metastases from Genito-Urinary Cancers in the Canton of Geneva (Switzerland): Study of Incidence, Management and Outcomes.瑞士日内瓦州泌尿生殖系统癌症脑转移：发病率、治疗及预后研究
Cancers (Basel). 2024 Oct 10;16(20):3437. doi: 10.3390/cancers16203437.
6
Current challenges in the treatment of gliomas: The molecular era.胶质瘤治疗中的当前挑战：分子时代
World J Clin Oncol. 2024 Aug 24;15(8):982-986. doi: 10.5306/wjco.v15.i8.982.
7
Stereotactic body radiotherapy for spinal oligometastases: a survey on patterns of practice on behalf of the Italian Association of Clinical Oncology and Radiotherapy (AIRO).立体定向体部放疗治疗脊柱寡转移瘤：意大利临床肿瘤学会和放射治疗学会（AIRO）的实践模式调查。
Clin Exp Metastasis. 2024 Oct;41(5):679-685. doi: 10.1007/s10585-024-10304-3. Epub 2024 Aug 1.
8
MGMT promoter methylation is a strong prognostic factor for survival after progression in high-grade gliomas.O6-甲基鸟嘌呤-DNA甲基转移酶（MGMT）启动子甲基化是高级别胶质瘤进展后生存的一个强有力的预后因素。
Chin Neurosurg J. 2024 Jul 24;10(1):24. doi: 10.1186/s41016-024-00375-2.
9
Treatment of IDH-mutant glioma in the INDIGO era.INDIGO时代IDH突变型胶质瘤的治疗
NPJ Precis Oncol. 2024 Jul 19;8(1):149. doi: 10.1038/s41698-024-00646-2.
10
State of the Art in Low-Grade Glioma Management: Insights From Isocitrate Dehydrogenase and Beyond.低级别胶质瘤管理的最新进展：异柠檬酸脱氢酶的启示及其他。
Am Soc Clin Oncol Educ Book. 2024 Jun;44(3):e431450. doi: 10.1200/EDBK_431450.
本文引用的文献
1
The 2021 WHO Classification of Tumors of the Central Nervous System: a summary.2021 年世卫组织中枢神经系统肿瘤分类：概述。
Neuro Oncol. 2021 Aug 2;23(8):1231-1251. doi: 10.1093/neuonc/noab106.
2
Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study.辅助和同步替莫唑胺治疗1p/19q未共缺失的间变性胶质瘤（CATNON；欧洲癌症研究与治疗组织26053-22054研究）：一项随机、开放标签的3期研究的第二次中期分析
Lancet Oncol. 2021 Jun;22(6):813-823. doi: 10.1016/S1470-2045(21)00090-5. Epub 2021 May 14.
3
CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas.CDKN2A 纯合缺失是弥漫性恶性 IDH 突变型神经胶质瘤的一个强烈不良预后因素。
Neuro Oncol. 2019 Dec 17;21(12):1519-1528. doi: 10.1093/neuonc/noz124.
4
Letter: When Less is More: Dexamethasone Dosing for Brain Tumors.信函：何时少即是多：脑肿瘤的地塞米松给药剂量
Neurosurgery. 2019 Sep 1;85(3):E607-E608. doi: 10.1093/neuros/nyz186.
Zotero 插件